Boston, MA, USA May 14, 2021 – Orbia Fluor & Energy Materials is pleased to announce today the launch of a new HFA-152a pMDI formulation development and filling service utilising their dedicated facilities located on Thornton Science Park, Chester, UK. 

This service is specifically intended to support clients with their early-stage development studies using HFA-152a, either those wishing to transition existing products, or who are seeking to formulate new molecules into a pMDI dosage form using the next generation low carbon footprint propellant. 

A range of services with be made available, from bench scale compatibility studies up to 5L pilot scale manufacturing as well as raw material and finished product testing, method development, transfer and validation. 

This new service will be supported by a highly skilled scientific and technical team with experience in delivering client projects. 

A UK IMP licence application is expected in 2022 to facilitate manufacture of samples suitable for use in clinical trials. 

The launch of this new service is part of a multi-year investment program to bring Zephex®  152a from the laboratory to the patient and follows an earlier announcement of a multimillion-pound sterling investment into a new cGMP Zephex®  152a medical propellant production facility. 

Boston, MA, USA May 14, 2021 – Orbia Fluor & Energy Materials is pleased to announce today the launch of a new HFA-152a pMDI formulation development and filling service utilising their dedicated facilities located on Thornton Science Park, Chester, UK. 

This service is specifically intended to support clients with their early-stage development studies using HFA-152a, either those wishing to transition existing products, or who are seeking to formulate new molecules into a pMDI dosage form using the next generation low carbon footprint propellant. 

A range of services with be made available, from bench scale compatibility studies up to 5L pilot scale manufacturing as well as raw material and finished product testing, method development, transfer and validation. 

This new service will be supported by a highly skilled scientific and technical team with experience in delivering client projects. 

A UK IMP licence application is expected in 2022 to facilitate manufacture of samples suitable for use in clinical trials. 

The launch of this new service is part of a multi-year investment program to bring Zephex®  152a from the laboratory to the patient and follows an earlier announcement of a multimillion-pound sterling investment into a new cGMP Zephex®  152a medical propellant production facility.